Industrialization of mAb production technology: the bioprocessing industry at a crossroads
about
A Single-use Strategy to Enable Manufacturing of Affordable BiologicsBiotechnological Trends in Spider and Scorpion Antivenom DevelopmentTunable recombinant protein expression in E. coli: enabler for continuous processing?Advances in recombinant antibody manufacturingToward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challengesGenomics in mammalian cell culture bioprocessingPassive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applicationsOptimized signal peptides for the development of high expressing CHO cell linesDevelopment of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxisLow level sequence variant analysis of recombinant proteins: an optimized approachThe ongoing evolution of antibody-based treatments for Ebola virus infection.Protein adsorption and transport in cation exchangers with a rigid backbone matrix with and without polymeric surface extenders.Cation-exchange chromatography of monoclonal antibodies: characterisation of a novel stationary phase designed for production-scale purificationCre-LoxP-regulated expression of monoclonal antibodies driven by an ovalbumin promoter in primary oviduct cells.Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product.Identification of a novel temperature sensitive promoter in CHO cells.Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco.Cell culture processes for monoclonal antibody production.SweetBac: a new approach for the production of mammalianised glycoproteins in insect cells.Rotavirus A-specific single-domain antibodies produced in baculovirus-infected insect larvae are protective in vivo.Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies.Computational design of a pH-sensitive IgG binding protein.Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug developmentCapacity planning for batch and perfusion bioprocesses across multiple biopharmaceutical facilitiesBridging the gap: facilities and technologies for development of early stage therapeutic mAb candidatesEncapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system.Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?Development and Characterization of a Guinea Pig-Adapted Sudan Virus.Monoclonal antibody therapy for Junin virus infection.Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic.Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches.Therapeutic antibodies for infectious diseases.Industry and regulatory experience of the glycosylation of monoclonal antibodies.Antibody-drug conjugates - a perfect synergy.Chemically programmed antibodies.Boronic acid-modified magnetic materials for antibody purificationContinuous downstream processing for high value biological products: A Review.The present state of the art in expression, production and characterization of monoclonal antibodies.DNA nanotechnology from the test tube to the cell.Nonbiological pharmacotherapies for the treatment of diabetic macular edema.
P2860
Q26738464-7FF5D9D8-E4B8-41A1-ADF5-75C260BEC7A2Q26741744-50DB4718-98A2-44AD-86BF-17CACBEC1320Q26750554-8FC5DC4D-8CC6-4B61-9181-B280463B100DQ26764949-96E11DA1-0693-43D0-8215-019553F5F087Q26995399-D53B1FE8-3316-48DC-8157-88831BCDFBE1Q27004367-A5FF3C65-9887-4B8B-9D5D-037809537D50Q28077984-4386476F-71C8-4DAE-95D0-97FB1CF98A2FQ28109355-B2750891-C562-4172-9CA1-8AF78BB3F3D0Q28601417-A475023A-6D11-4B81-8EDE-BE53F6DD70FCQ28727418-0B41BDD1-6F8D-45FC-B315-51CCB6B23013Q30235022-90CE1AD9-0007-4B23-B980-BB67BD22F13CQ30453535-5AB76269-3D46-455C-9ADD-3F8825995B72Q33608532-6AB522DF-5B9C-47DF-9241-CF357FF9E826Q33793459-AC8202F1-9140-424B-9951-39DD5FD51AEFQ33826350-46C5BAD2-FD9B-4765-A3D2-CAED0ED53DE2Q33898938-900F4404-019E-4F74-8FA7-1406936CC1EFQ33957908-8743C3E9-6B21-4AB4-907F-92E37FE61151Q34125491-88F13393-96EA-4257-87A1-98F66FCC6D2BQ34224840-8C2DA0C0-3C63-40EC-B4CE-746AA51CAA49Q34407012-0C7D4DDA-B3AD-4E9E-A417-476D64691D9BQ34997869-46AF1462-C902-4B0C-8ECD-FDD144E443A8Q35079293-941A7093-4C57-4E39-A844-691207943EE3Q35105725-B016C860-013A-4413-B0EC-DE7CBAD9E820Q35557018-B29EF73B-4142-4112-A764-F8C077D84645Q35578028-48730D1D-0B33-43B1-A71A-B66FB77FF1E0Q35723422-CA32D361-3800-476A-A473-B1A756B5858BQ36269593-2F5DF35C-C62C-4225-911C-9A6A15A6B919Q36433906-9BF3B842-B843-40EB-9A18-C4D5C47AB555Q36831453-E2CF4FCA-C5EE-451B-9F3A-8A30DB9A3D5DQ37134982-8C673717-896F-4716-8174-806D57037C95Q37496596-E6ED95B6-2411-493B-9ED3-9EF4ACE63C5DQ37669319-12D18312-E404-4BD5-BA20-1BD0EC586287Q37916701-A66294C4-5960-44F0-8959-D79EB4059EBBQ38014923-981A6FA1-E24D-470D-AF37-4E2B24B0F039Q38196060-1E9767B8-C13C-4400-BC36-1B5651E72B85Q38311042-72107DE7-2334-4AFA-B73A-A28CFCE1EA81Q38543755-11846F11-A59D-4E13-B0B0-AED0674B91E4Q38572163-5E6E8116-7060-4EC4-A1D1-E8414957B91CQ38578352-EB04C029-8BEE-4CA8-A543-6567AD04ED07Q38622256-8EADB22B-DE6C-49A8-B73E-023AC835EC9B
P2860
Industrialization of mAb production technology: the bioprocessing industry at a crossroads
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Industrialization of mAb produ ...... ssing industry at a crossroads
@ast
Industrialization of mAb produ ...... ssing industry at a crossroads
@en
Industrialization of mAb produ ...... ssing industry at a crossroads
@nl
type
label
Industrialization of mAb produ ...... ssing industry at a crossroads
@ast
Industrialization of mAb produ ...... ssing industry at a crossroads
@en
Industrialization of mAb produ ...... ssing industry at a crossroads
@nl
prefLabel
Industrialization of mAb produ ...... ssing industry at a crossroads
@ast
Industrialization of mAb produ ...... ssing industry at a crossroads
@en
Industrialization of mAb produ ...... ssing industry at a crossroads
@nl
P2860
P3181
P356
P1476
Industrialization of mAb produ ...... ssing industry at a crossroads
@en
P2093
Brian Kelley
P2860
P304
P3181
P356
10.4161/MABS.1.5.9448
P407
P577
2009-01-01T00:00:00Z